Back

Introduction

1 September 2019 (13:00 - 13:05)
Organised by:
Congress Presentation Part of: Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
The need for urgency in treating hyperlipidemia in post-ACS patients
Professor F. Schiele (Besancon, FR)
Presentation thumbnail
Enriching the PCSK9i evidence - The most recent analyses from ODYSSEY OUTCOMES
Professor J. Jukema (Leiden, NL)
Presentation thumbnail
Evaluating the benefit/risk and safety profile of PCSK9 inhibitors - Clinical and economic implications
Doctor C. Ballantyne (Houston, US)
Presentation thumbnail
Panel discussion
Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)
Presentation thumbnail
Conclusion and key takeaways
Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)

Access the full session

Session thumbnail
Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes

The Event

Event poster

ESC Congress 2019

1 September 2019 13:00 CET
You may be interested in
thumbnail
Congress Session
Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
30 August 2025
thumbnail
Congress Presentation
Introduction and objectives
10 May 2023
thumbnail
Congress Presentation
Welcome and introduction.
23 May 2022
thumbnail
Congress Presentation
Breaking through: CETP inhibitors and the future of lipid therapy
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources